Tarsus Pharmaceuticals (TARS) CEO On First & Only Demodex Blepharitis Treatment

Tarsus Pharmaceuticals (TARS) has the first and only approved treatment for Demodex Blepharitis, Xdemvy. The FDA approved Xdemvy for treatment of Demodex Blepharitis in July 2023. CEO of Tarsus Pharmaceuticals Bobby Azamian, MD, PhD joins Oliver Renick to discuss the biopharmaceutical company. The company focuses on novel therapies or ophthalmic conditions. Tune in to find out more about the stock market today.

Morning Trade Live

09 Jan 2024

SHARE

ON AIR
12:00 am
Fast Market
replay
ON AIR
12:00 am
Fast Market
REPLAY
1:00 am
Trading 360
REPLAY
2:00 am
Next Gen Investing
REPLAY
education
3:00 am
Your First Trade
REPLAY
3:30 am
Trading 360
REPLAY
4:30 am
Next Gen Investing
REPLAY
education
5:30 am
Your First Trade
REPLAY
6:00 am
Fast Market
REPLAY
7:00 am
Futures
8:00 am
Morning Trade Live
10:00 am
Trading 360
11:00 am
Fast Market
12:00 pm
Next Gen Investing
1:00 pm
The Watch List
2:00 pm
Market On Close
3:30 pm
Market Overtime
4:00 pm
Trading 360
REPLAY
5:00 pm
Fast Market
REPLAY
6:00 pm
Next Gen Investing
REPLAY
7:00 pm
Market Overtime
REPLAY
education
7:30 pm
Your First Trade
REPLAY
8:00 pm
Trading 360
REPLAY
9:00 pm
Market Overtime
REPLAY
education
9:30 pm
Your First Trade
REPLAY
10:00 pm
Fast Market
REPLAY
11:00 pm
Trading 360
REPLAY

Get the Market Minute

Daily insights for every investor

coming soon

We are now

coming soon

We are now